Latest Hydromorphone Stories
CORALVILLE, Iowa, Dec.
MarketReportsOnline.com adds "The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-2019)" report to its research store. Dallas,
KemPharm's Intellectual Property Estate Now Includes Composition of Matter Patents for Two Ligand Activated Technology (LAT) Opioid Prodrugs - KP511 and KP201 CORALVILLE, Iowa, Sept.
Results Validating the Multi-Modal Mechanism of Action Would Provide the Basis for Differentiating LevoCap ER from other Pain Therapies NEW YORK, Sept.
CUPERTINO, Calif., Aug. 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2014.
Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent Prodrugs
DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S.
CUPERTINO, Calif., May 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.
CUPERTINO, Calif., May 1, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2014.
Patent Protection for KP511 Extends KemPharm's Intellectual Property Estate for Leading Franchise of Abuse-Deterrent Opioid Medications CORALVILLE, Iowa, April 30, 2014 /PRNewswire/
- A volcanic mudflow.